Rigel Pharmaceuticals (RIGL) Tops Q2 EPS by 67c; Offers Guidance
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $46.64 +1.72%
Revenue Growth %: +15.2%
Financial Fact:
Total costs and expenses: 26.5M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +15.2%
Financial Fact:
Total costs and expenses: 26.5M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Rigel Pharmaceuticals (NASDAQ: RIGL) reported Q2 EPS of $0.88, $0.67 better than the analyst estimate of $0.21. Revenue for the quarter came in at $78.7 million versus the consensus estimate of $54.94 million.
GUIDANCE:
Rigel Pharmaceuticals sees FY2026 revenue of $285-295 million, versus the consensus of $278.9 million.
For earnings history and earnings-related data on Rigel Pharmaceuticals (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. and Denmark close in on a Greenland deal - Reuters
- Ximen Mining launches $350,000 bridge placement for Kenville mine
- Trump says U.S. and Denmark reached permanent security deal over Greenland
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
